Study Evaluating GAP-486 in Heart Rhythm

Wyeth

Status and phase: Terminated; Phase 2

Conditions: Arrhythmia

Treatments: Drug: GAP-486 (ZP-123); Drug: 0.9% Sodium Chloride, USP

Study type: Interventional

Funder types: Industry

Identifiers

NCT00137293

3163K1-201

Details and patient eligibility

About

The purpose of this study is to learn the effects of a test drug on heart rhythm, and to provide additional data to see if the test drug is well tolerated and safe.

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients undergoing an electrophysiology study for evaluation of heart rhythm.

Exclusion criteria

• Patients with uncontrolled blood pressure
• Patients with certain cardiac risk factors
• Patients with significant kidney or liver problems